Joshua K. Sabari, MD

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

Other considerations between KRAS targeting treatments in patients with KRAS+ mutated NSCLC.

An overview of recognizing and managing common immune-related and systemic adverse events with immune checkpoint inhibitors, chemotherapy and KRAS targeted therapies in NSCLC.

Clinical trial efficacy and safety data between KRAS G12C inhibitors that inform initial treatment selection for patients with NSCLC.

An overview of the role of KRAS G12C inhibitors in the second line and beyond for KRAS G12C mutated NSCLCs after progression on platinum-based chemotherapy.

Cinical trial data and guidelines on optimal first-line regimens for metastatic KRAS mutated lung adenocarcinoma.

Background on KRAS mutations in lung adenocarcinoma, including the prevalence, prognosis, and challenges in treating patients with NSCLC.

Joshua K. Sabari, MD, offers key takeaways on treating patients with EGFR+ non–small cell lung cancer, highlighting the safety profile.

Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.

An expert on EGFR+ non–small cell lung cancer discusses factors that influence treatment decisions.

An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.

Joshua K. Sabari, MD, reviews clinical trial data from FLAURA2 on osimertinib plus chemotherapy in patients with EGFR-mutated advanced lung cancer.

A medical oncologist provides an overview of treatment options available for patients with EGFR+ non–small cell lung cancer.

Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.

Joshua K. Sabari, MD, discusses where research on LY3537982 for patients with KRAS G12C-mutant advanced solid tumors is headed.

Joshua K. Sabari, MD, discusses the importance of targeting the KRAS biomarker and what inhibitors currently exist for patients with KRAS G12C-mutant advanced solid tumors.

Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.

Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.

An overview of the CARMEN-LC03 and CARMEN-LC04 trials investigating tusa in different treatment settings for NSCLC and their impact on treatment approaches is provided.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

The transformative potential of antibody drug conjugates in NSCLC treatment is discussed, encompassing their design, bystander effect, biomarkers, and impact on the treatment landscape.

Dr. Florez and Dr. Sabari discuss standards of care for different patient populations in NSCLC.

Experts share their approach to CEACAM5 testing, including the testing procedure, patient selection criteria, and timing of testing.

The role of CEACAM5, its expression in NSCLC, and its potential as a therapeutic target are thoroughly examined, including its impact on tumorigenesis and prognosis in NSCLC patients.

The discussion centered around emergent biomarkers and targeted therapies in NSCLC, exploring targets like CEACAM5, TROP2, HER3, cMET, and the potential role of antibody drug conjugates in refractory disease.

A comprehensive overview of the current landscape of non-small cell lung cancer (NSCLC), highlighting the impact of biomarkers on treatment selection.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

Joshua K. Sabari, MD, discusses the shortage of carboplatin, its impacts, and how oncologist can still treat patients.

Joshua K. Sabari, MD, explains how the shortage of drugs in the oncology space, including carboplatin and cisplatin, began.

Joshua K. Sabari, MD, discusses his use of durvalumab in the frontline setting for the treatment of patients with small-cell lung cancer and where he sees the role for the treatment.